As previously announced, Allergan paid approximately $150 million for all assets relating to Aczone gel 5%. Allergan expects to launch Aczone gel 5% in the fourth quarter of 2008 in the US and Canada.
David Pyott, chairman of the board and CEO of Allergan, said: “We are pleased with the opportunity to grow our franchise in medical dermatology where there is a continuous need for new treatment options and strong growth potential.”